Chia-Yu Hsu

Chia-Yu Hsu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2022 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
MLMeng Lee
Meng Lee
CCChun-Yu Cheng
Chun-Yu Cheng
YWYi-Ling Wu
Yi-Ling Wu
JLJiann-Der Lee
Jiann-Der Lee
CHChia-Yu Hsu
Chia-Yu Hsu
BOBruce Ovbiagele
Bruce Ovbiagele
An elevated low-density lipoprotein cholesterol (LDL-C) level is a risk factor for cardiovascular disease, including ischemic stroke.1 For patients with a history of ischemic stroke, an elevated LDL-C level is associated with an increased risk of subsequent major cardiovascular events.2 More intensive compared with less intensive LDL-C–lowering statin-based therapies are associated with reduced major cardiovascular events in patients with established atherosclerotic cardiovascular disease.3 However, the results of LDL lowering with statins in secondary stroke prevention trials are inconsistent. An initial meta-analysis of randomized clinical trials showed that intensive LDL-C reduction with statins was associated with a significantly reduced risk of recurrent stroke.4 A subsequent meta-analysis of randomized clinical trials showed that statins were associated with a reduction in the risk of ischemic strokes and cardiovascular events, but the reduction of recurrent stroke did not reach statistical significance.5 In addition to their LDL-C–lowering effects, statins may exhibit cardiovascular protection via their pleiotropic effects.6,7 The antithrombotic effect of statins may provide additional reduction in ischemic events but may increase the risk of intracranial hemorrhage in patients with ischemic stroke.7,8

20 January 2016 in SpringerPlus
Verified
Journal Article
Open access
PDF file
YPYi-Ting Pan
Yi-Ting Pan
JLJiann-Der Lee
Jiann-Der Lee
YLYa-Hui Lin
Ya-Hui Lin
YHYing-Chih Huang
Ying-Chih Huang
HWHsu-Huei Weng
Hsu-Huei Weng
YHYenchu Huang
Yenchu Huang
The purpose of this study was to analyze the outcomes and complications between stroke subtypes after intravenous thrombolysis. A total of 471 patients with acute ischemic stroke after intravenous thrombolysis from January 2007 to April 2014 were enrolled and classified according to the Trial of Org 10172 in Acute Stroke Treatment. A multivariate logistic regression model was used to evaluate the outcomes and complications among stroke subtypes after adjusting for baseline variables. Of the 471 patients, 117 (25.1 %) had large-artery atherosclerosis (LAA), 148 (31.8 %) had cardioembolism (CE), 82 (17.6 %) had small vessel disease (SVD), 119 (25.5 %) had undetermined etiology, and 5 (1.1 %) had other determined etiology. The patients with SVD had the mildest initial stroke severity and highest ratio of good and favorable outcomes, whereas those with CE had a higher rate of symptomatic intracranial hemorrhage (sICH) than those with SVD. After adjusting for confounding factors, the ratio of favorable outcome in the patients with SVD stroke was higher than in those with LAA. SVD was associated with a significantly lower rate of any hemorrhage compared to other stroke subtypes, whereas there were no differences in sICH or mortality between stroke subtypes. A lower initial National Institutes of Health Stroke Scale score was associated with good and favorable outcomes, and lower rates of sICH and mortality. The patients with SVD after intravenous thrombolysis had better outcomes and a lower rate of hemorrhage even after adjusting for confounding factors. Stroke severity was an independent factor associated with better functional outcomes, sICH and mortality.

5 December 2018 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CCChun-Yu Cheng
Chun-Yu Cheng
CHChia-Yu Hsu
Chia-Yu Hsu
TWTing‑Chung Wang
Ting‑Chung Wang
YJYa-Chung Jeng
Ya-Chung Jeng
WYWei Hsun Yang
Wei Hsun Yang
Literature regarding cardiac deaths in hemorrhagic stroke patients is few. The aim of this study was to investigate the incidence and risk factors of cardiac death in hemorrhagic stroke patients. We used the multiple causes of death database from the Centers for Disease Control and Prevention Wide-ranging Online Data of the United States. We identified death certificates from 2006 to 2010 with hemorrhagic stroke (International Classification of Disease, Tenth Revision (ICD-10) code I60-62), or ischemic stroke (ICD-10 code I63), and evaluated the frequency and risk factors of reporting MI (ICD-10 code I20-25) or arrhythmias (ICD-10 code I44-45, I47-49) as the main cause of death in these populations. Over the five-year period, 224,359 death certificates that mentioned hemorrhagic stroke were identified, and the cause of death was MI in 8.95% and arrhythmia in 7.28% patients. With autopsy confirmation, the incidences of MI and arrhythmias in the hemorrhagic stroke group were still lower than the ischemic group. The odds ratio of reporting arrhythmias as a cause of death in hospitalized population was higher. A substantial percentage of hemorrhagic stroke patients had cardiac death. Greater efforts are needed to closely monitor high-risk groups such as females and the elderly.

1 June 2022 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
WHWei-Tse Hung
Wei-Tse Hung
YCYuan-Jung Chen
Yuan-Jung Chen
CCChun-Yu Cheng
Chun-Yu Cheng
BOBruce Ovbiagele
Bruce Ovbiagele
MLMeng Lee
Meng Lee
CHChia-Yu Hsu
Chia-Yu Hsu